Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Azacitidine 56Cyclophosphamide 44fludarabine phosphate 42fludarabine 37Decitabine 27venetoclax 26Cytarabine 25Tacrolimus 20Specimen Handling 18Filgrastim 18Busulfan 18Melphalan 17Whole-Body Irradiation 16Mycophenolic Acid 16Antilymphocyte Serum 14Granulocyte Colony-Stimulating Factor 12Clofarabine 12Biopsy 12Peripheral Blood Stem Cell Transplantation 11Injections 11Etoposide 11Methotrexate 10thymoglobulin 9Thiotepa 9Stem Cell Transplantation 9Lenalidomide 9decitabine and cedazuridine drug combination 8aldesleukin 8Sirolimus 8Nivolumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Myelodysplastic Syndromes × orludodstat × Clear all
NCT03404726 2022-01-11

A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies

Bayer

Phase 1 Terminated
40 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡